EP1746971A1 - Dermatologische zusammensetzung zur behandlung von pigmentierungsstörungen der haut - Google Patents
Dermatologische zusammensetzung zur behandlung von pigmentierungsstörungen der hautInfo
- Publication number
- EP1746971A1 EP1746971A1 EP05770836A EP05770836A EP1746971A1 EP 1746971 A1 EP1746971 A1 EP 1746971A1 EP 05770836 A EP05770836 A EP 05770836A EP 05770836 A EP05770836 A EP 05770836A EP 1746971 A1 EP1746971 A1 EP 1746971A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- skin
- fatty acid
- mequinol
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000002537 cosmetic Substances 0.000 claims abstract description 15
- 229960003505 mequinol Drugs 0.000 claims abstract description 15
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 15
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 12
- 230000000475 sunscreen effect Effects 0.000 claims description 6
- 239000000516 sunscreening agent Substances 0.000 claims description 6
- 208000003351 Melanosis Diseases 0.000 claims description 5
- 206010008570 Chloasma Diseases 0.000 claims description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000012641 Pigmentation disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 2
- 235000021342 arachidonic acid Nutrition 0.000 claims description 2
- 229940114079 arachidonic acid Drugs 0.000 claims description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- 230000019612 pigmentation Effects 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000007854 depigmenting agent Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 13
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 208000000069 hyperpigmentation Diseases 0.000 description 5
- 230000003810 hyperpigmentation Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- HEAHZSUCFKFERC-LRVMPXQBSA-N [(2e)-2-[[4-[(z)-[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanylidene]methyl]phenyl]methylidene]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)\C2=C/C(C=C1)=CC=C1\C=C/1C(=O)C2(CS(O)(=O)=O)CCC\1C2(C)C HEAHZSUCFKFERC-LRVMPXQBSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003747 ecamsule Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- the invention relates to a skin depigmenting composition
- a skin depigmenting composition comprising, in a physiologically acceptable medium, mequinol (or 4-hydroxyanisole), and at least one unsaturated or polyunsaturated fatty acid and its pharmaceutical or cosmetic use.
- the composition according to the invention may also contain a sunscreen.
- the pigmentation of the skin results from the synthesis of melanin in the melanocytes of the dermis by the transformation of tyrosine under the influence of a cuproprotein enzyme tyrosinase.
- Mequinol is a compound whose depigmenting activity is known. Indeed it acts as a substrate for tyrosinase and therefore blocks the mechanism of melanin synthesis in the dermis (Riley P, Journal of Pathology (1969), 97 (2), 185-191) Indeed, disorders Pigments such as hyperpigmentation are the result of excessive production of melanin. By blocking or decreasing this synthesis, one can obtain a depigmentation effect
- the Applicant has surprisingly discovered that the combination of mequinol and a fatty acid makes it possible to obtain, by synergistic effect, a depigmenting response much more effective than that obtained with mequinol alone and above all to provide better comfort of use.
- the invention relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, mequinol and an unsaturated fatty acid.
- physiologically acceptable medium means a medium compatible with the skin, the mucous membranes and / or the integuments.
- fatty acid is meant a constituent of lipids.
- the fatty acids differ from each other by their chain length and their degree of saturation, namely the number of carbon constituting the chain and the nature of the bonds, single or double, connecting the carbon atoms to each other.
- saturated fatty acid according to the invention means the unsaturated fatty acids and the polyunsaturated fatty acids.
- unsaturated fatty acid By way of nonlimiting example of unsaturated fatty acid according to the invention, mention may be made of linoleic acid, arachidonic acid, sorbic acid, docosahexaenoic acid, or eicosapentaenoic acid.
- composition containing the combination according to the invention makes it possible to obtain a clear whitening of the skin.
- the invention also relates to a depigmenting composition for the skin comprising, in a physiologically acceptable medium, mequinol, at least one unsaturated or polyunsaturated fatty acid and at least one sunscreen.
- the composition according to the invention advantageously comprises between 0.0001 and 20% by weight of mequinol relative to the total weight of the composition and between 0.0001 and 20% by weight of fatty acid relative to the total weight of the composition, and preferably, respectively, between 0.001 and 10% by weight of mequinol relative to the total weight of the composition and between 0.025 and 10% by weight of fatty acid relative to the total weight of the composition.
- the composition can also comprise at least one sunscreen in preferential concentrations ranging from 0.001 to 30.00% by weight relative to the total weight of the composition.
- the composition may include several sun filters.
- each sunscreen can be added at a concentration ranging from 0.001 to 20% by weight relative to the total weight of the composition.
- compositions according to the invention can also comprise any additive usually used in the cosmetic or pharmaceutical field, such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids usual, mineral or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, soothing and protective agents for the skin.
- any additive usually used in the cosmetic or pharmaceutical field such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids usual, mineral or organic, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, soothing and protective agents for the skin.
- any additive usually used in the cosmetic or pharmaceutical field such as sequestrants, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids usual, mineral or organic, perfume
- the present invention also relates to a pharmaceutical composition as described above as a medicament.
- the present invention also relates to a cosmetic composition.
- compositions containing the combination according to the invention can have all the galenical forms normally used for a topical application, for example under form of solutions, gels, dispersions of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (E / H), or suspensions or emulsions of soft, semi-solid or solid consistency of the cream or gel type, or alternatively of microemulsions, microcapsules, microparticles or vesicular dispersions of the ionic and / or nonionic type.
- These compositions are prepared according to the usual methods.
- the cosmetic or dermatological compositions of the invention may contain adjuvants customary in the cosmetic or dermatological field, such as emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents other than titanium oxide and ⁇ -hydroxy acid, preservatives, antioxidants, perfumes, fillers, filters and coloring matters.
- adjuvants customary in the cosmetic or dermatological field, such as emulsifiers, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents other than titanium oxide and ⁇ -hydroxy acid, preservatives, antioxidants, perfumes, fillers, filters and coloring matters.
- the amounts of these various adjuvants are those conventionally used in the cosmetic and / or dermatological fields, and for example from 0.01% to 20% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid vesicles.
- the invention also relates to the use of the composition according to the invention as described above in the pharmaceutical and cosmetic field.
- compositions of the invention are particularly suitable for the treatment and prevention of pigmentation disorders.
- the compositions of the invention are suitable for the treatment and prevention of hyperpigmentary disorders such as melasma, chloasma, lentigines, senile lentigo, vitiligo, freckles, post-inflammatory hyperpigmentations due to abrasion. , a burn, a scar, a dermatosis, a contact allergy; nevi, hyperpigmentations with genetic determinism, hyperpigmentations of metabolic or drug origin, melanomas or any other pigmentary lesions, in particular those induced by photo-induced or chronological aging of the skin and integuments.
- compositions according to the invention are suitable for the treatment of melasma.
- the compositions according to the invention also find an application in the cosmetic field, in particular in the protection against the harmful aspects of the sun, in particular, against pigmentary spots.
- the invention also relates to a non-therapeutic cosmetic treatment process for beautifying the skin and / or improving its surface appearance, characterized in that a composition is applied to the skin and / or its integuments comprising mequinol and an unsaturated or polyunsaturated fatty acid.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0405283A FR2870124B1 (fr) | 2004-05-14 | 2004-05-14 | Composition dermatologique pour le traitement des desordres pigmentaires de la peau |
| PCT/FR2005/001213 WO2005115324A1 (fr) | 2004-05-14 | 2005-05-13 | Composition dermatologique pour le traitement des desordres pigmentaires de la peau |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1746971A1 true EP1746971A1 (de) | 2007-01-31 |
Family
ID=34945901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP05770836A Withdrawn EP1746971A1 (de) | 2004-05-14 | 2005-05-13 | Dermatologische zusammensetzung zur behandlung von pigmentierungsstörungen der haut |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1746971A1 (de) |
| JP (1) | JP2007537218A (de) |
| CA (1) | CA2564100A1 (de) |
| FR (1) | FR2870124B1 (de) |
| WO (1) | WO2005115324A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008047633A1 (fr) * | 2006-10-10 | 2008-04-24 | Maruha Corporation | Agent de blanchiment de la peau contenant un composé aliphatique |
| FR2984730A1 (fr) * | 2011-12-22 | 2013-06-28 | Diverchim | Nouvelles compositions cosmetiques anti-age et depigmentantes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2614474B2 (ja) * | 1988-01-20 | 1997-05-28 | サンスター株式会社 | 美白化粧料 |
| JP2628328B2 (ja) * | 1988-01-20 | 1997-07-09 | サンスター株式会社 | 美白化粧料 |
| JP2780989B2 (ja) * | 1989-01-28 | 1998-07-30 | 三省製薬株式会社 | 外用剤 |
| US5932612A (en) * | 1997-08-05 | 1999-08-03 | Medicis Pharmaceutical Corp. | Compositions and systems for the treatment of hyperpigmentation |
| JP3176572B2 (ja) * | 1997-09-02 | 2001-06-18 | エフ・ディ−・ケイ株式会社 | アルカリ電池 |
| JP3826227B2 (ja) * | 1997-09-12 | 2006-09-27 | 宮田工業株式会社 | バッテリーパック |
-
2004
- 2004-05-14 FR FR0405283A patent/FR2870124B1/fr not_active Expired - Fee Related
-
2005
- 2005-05-13 EP EP05770836A patent/EP1746971A1/de not_active Withdrawn
- 2005-05-13 WO PCT/FR2005/001213 patent/WO2005115324A1/fr not_active Ceased
- 2005-05-13 CA CA002564100A patent/CA2564100A1/fr not_active Abandoned
- 2005-05-13 JP JP2007512293A patent/JP2007537218A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2005115324A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005115324A1 (fr) | 2005-12-08 |
| JP2007537218A (ja) | 2007-12-20 |
| FR2870124A1 (fr) | 2005-11-18 |
| CA2564100A1 (fr) | 2005-12-08 |
| FR2870124B1 (fr) | 2006-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1252882B1 (de) | Verfahren zur Erhöhung der Schwellentoleranz bei empfindlicher Haut | |
| EP0661038A1 (de) | Depigmentierendes Mittel zur gleichzeitigen Behandlung von Hautoberschichten und Hauttiefschichten | |
| EP1064931A1 (de) | Kosmetisches Mittel enthaltend mindestens einen Hydroxystilben und Ascorbinsaüre | |
| EP0747043A1 (de) | Verwendung von Salicylsäure-Derivativen zur Hautbleichung | |
| CA2685482A1 (fr) | Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations | |
| FR2798590A1 (fr) | Utilisation de l'alverine pour diminuer les rides | |
| EP0771557A1 (de) | Verwendung einer Ascorbinsäure zur Behandlung von Seborrhea in einer kosmetischen oder/und dermatologischen Zusammensetzung | |
| FR2849597A1 (fr) | Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives | |
| CA2568262A1 (fr) | Gel depigmentant hydroalcoolique comprenant du mequinol et de l'adapalene | |
| EP1737457A2 (de) | Verwendung einer mit nikotinsäure oder nikotinsäureamid in form eines depigmentierungsmittels assoziierten sphingoid-basis | |
| EP1019017B1 (de) | Kombination aus phenolderivaten und einem extrakt von iridaceen zur depigmentierung der haut oder ihrer anhangsgebilde und diese kombination enthaltende zusammensetzung | |
| EP1746971A1 (de) | Dermatologische zusammensetzung zur behandlung von pigmentierungsstörungen der haut | |
| EP1404327B1 (de) | Dermatologische zusammensetzungen, die nikotinsäure oder nikotinsäureamid und sphingoid-base enthalten | |
| EP1755541A2 (de) | Pharmazeutische oder kosmetische zusammensetzung mit mequinol und mindestens einem depigmentierungsmittel | |
| FR2946249A1 (fr) | Compositions topiques depigmentantes, et leurs utilisations. | |
| EP1566168A1 (de) | Hautkosmetische Zubereitungen zur Depigmentierung und deren Verwendung | |
| EP1755542A1 (de) | Mequinol-basierte dermatologische depigmentierungszusammensetzung | |
| EP0940140A1 (de) | Äusserlich verwendbare zusammensetzung aus alpha-hydroxysäuren und ceramiden zur behandlung von dermatologische erkrankungen | |
| WO2007066041A2 (fr) | Composition dépigmentante de la peau comprenant un dérivé d'acide naphtoique | |
| CA2511901A1 (fr) | Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives | |
| FR3132638A1 (fr) | Utilisation de rhamnolipide(s) pour prévenir la coloration des points noirs cutanés | |
| FR2788693A1 (fr) | Utilisation du miel non fermente comme agent depigmentant | |
| EP1252883A1 (de) | Verfahren zur teilweisen oder ganzen Reduzierung von Symptomen die mit der Freisetzung von Histamin im menschlichen Körper zusammenhängen | |
| WO2002005779A1 (fr) | Composition, notamment cosmetique, renfermant la dhea et/ou ses precurseurs ou derives, et une vitamine | |
| FR3098394A1 (fr) | Composition comprenant au moins une oxazoline pour inhiber la croissance de levure du genre Malassezia impliquée notamment dans les croûtes de lait |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20061214 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: LV |
|
| RAX | Requested extension states of the european patent have changed |
Extension state: LV Payment date: 20061214 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: COUSIN, CECILE Inventor name: PELISSON, ISABELLE,RES. MEDITERRANEE |
|
| 17Q | First examination report despatched |
Effective date: 20070509 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GALDERMA RESEARCH & DEVELOPMENT |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20071120 |